BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.
不列顛哥倫比亞省溫哥華--（Newsfile Corp.-2024 年 4 月 15 日）- BetterLife 製藥公司 (CSE: BETR)（場外交易代碼：BETR）是一家專注於精神障礙尖端療法開發和商業化的新興生物技術公司，將參與2024年的Bloom Burton & Co.醫療保健投資者會議，將於 4 月 16 日和 17 日在大多倫多會議中心舉行。
| Dates: | Tuesday April 16, 2024-Wednesday April 17, 2024 |
| Time: | 8:30 AM-5:00 PM ET |
| Location: | Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 |
| 日期： | 2024 年 4 月 16 日星期二至 2024 年 4 月 17 日星期三 |
| 時間： | 美國東部時間上午 8:30 至下午 5:00 |
| 地點： | 大多倫多會議中心， 北樓 255 Front St W 安大略省多倫多 M5V 2W6 |
Dr. Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer will be speaking at 04:00pm ET on April 16th. Interested parties can register to attend here.
首席執行官艾哈邁德·多魯迪安博士和首席運營官胡什曼德·謝什巴拉達蘭博士將在美國東部時間4月16日下午4點發表講話。有興趣的人士可以在這裏註冊參加。
Members of the BetterLife Pharma Inc. management team will also be taking meetings throughout the day.
BetterLife Pharma Inc.管理團隊的成員也將全天開會。
To register for the 2024 Bloom Burton & Co. Healthcare Investor Conference, please follow this link.
註冊參加 2024 年 Bloom Burton & Co.醫療保健投資者大會，請點擊此鏈接。
About BetterLife Pharma Inc.
關於BetterLife Pharma Inc.
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
BetterLife Pharma Inc. 是一家新興的生物技術公司，主要專注於開發和商業化兩種用於治療神經精神和神經系統疾病的化合物，即 BETR-001 和 BETR-002。Betr-001處於臨床前和支持IND的研究中，是一種非致幻和非對照的迷幻藥衍生物，其獨特之處在於它不受監管，因此可以自我給藥。BetterLife 的 BETR-001 合成專利消除了監管障礙，其成分和使用方法的待審專利涵蓋了重度抑鬱症、焦慮症和神經病理性疼痛以及其他神經精神和神經系統疾病的治療。Betr-002 目前處於臨床前和支持臨床試驗的研究中，基於厚朴樹皮的活性抗焦慮成分厚朴酚。BetterLife正在申請的使用方法和配方專利涵蓋了包括苯二氮卓類藥物依賴在內的焦慮相關疾病的治療。BetterLife還擁有一種用於治療 COVID-19 等病毒感染的候選藥物，並且正在爲進一步開發尋找戰略替代方案。
About the Conference:
關於會議：
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
Bloom Burton & Co.醫療保健投資者會議彙集了對加拿大醫療行業最新發展感興趣的美國、加拿大和國際投資者。與會者將有機會通過演講和非公開會議從加拿大主要上市公司和私營公司那裏獲得公司最新情況。
About Bloom Burton & Co.:
關於布魯姆·伯頓公司:
Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF).
Bloom Burton & Co. 是一家致力於加快投資者和公司在醫療保健領域的回報的公司。Bloom Burton 擁有一支由醫學、科學、行業和資本市場專業人士組成的經驗豐富的團隊，他們進行深入的勤奮工作，再加上我們的創造性和創業精神，幫助我們的客戶實現正確的盈利活動。Bloom Burton及其附屬公司提供籌資、併購諮詢、股票研究、戰略諮詢以及公司創建和孵化服務。布魯姆·伯頓證券公司是加拿大投資監管組織（CIRO）的成員，也是加拿大投資者保護基金（CIPF）的成員。
For questions and further information please contact:
David Melles
Investor Relations Manager
1-778-887-1928
David.Melles@blifepharma.com
如有疑問和更多信息，請聯繫：
大衛·梅勒斯
投資者關係經理
1-778-887-1928
David.Melles@blifepharma.com
譯文內容由第三人軟體翻譯。